Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 in moderate to severe Crohn's disease
MOH_2019-04-08_006077Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in Crohn's disease (3 arms), sponsored by Bristol Myers Squibb. Started Mar 2019; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2019-04-08_006077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-08_006077.